Bartlett Adam W, McMullan Brendan, Rawlinson William D, Palasanthiran Pamela
School of Women's and Children's Health, UNSW Sydney, Sydney, Australia.
Biostatistics and Databases Program, The Kirby Institute, UNSW Sydney, Sydney, Australia.
Rev Med Virol. 2017 Sep 6. doi: 10.1002/rmv.1938.
Congenital CMV is one of the commonest congenital infections and a recognised cause of sensorineural hearing loss and neurodevelopmental impairment. Ninety percent are clinically inapparent at birth but are reported to be at risk of developing such abnormalities throughout childhood, the extent of which requires further elucidation.
A systematic literature review was conducted using Medline and Embase databases, manual citation review, and personal libraries for articles reporting primary data on hearing and neurodevelopmental outcomes for children with asymptomatic congenital CMV. PROSPERO registration number CRD42015025407.
Thirty-seven of 480 articles identified between 1969 and 2016 met the eligibility criteria. Twenty-nine of these contributed primary data on hearing outcomes and 20 on neurodevelopmental outcomes (12 of the 37 studies contributed data on both). Cumulative incidence of sensorineural hearing loss with follow-up to at least 5 years was 7% to 11%, which is more than healthy controls but less than children with symptomatic congenital CMV (34%-41%). The onset, course, and severity of hearing loss was variable with no reliable virological prognostic marker. In comparison to controls, children with asymptomatic congenital CMV did not perform worse than controls in neurodevelopmental assessments and performed better than children with symptomatic congenital CMV.
Studies show children with asymptomatic congenital CMV are at increased risk of developing hearing loss but perform equally well on neurodevelopmental assessments when compared with healthy controls. There is no reliable virological marker to determine which infants will develop sequelae. Regular follow-up until school entry is supported by the literature.
先天性巨细胞病毒感染是最常见的先天性感染之一,是感音神经性听力损失和神经发育障碍的公认病因。90%的患儿出生时临床症状不明显,但据报道在整个儿童期都有发生此类异常的风险,其发生程度尚需进一步阐明。
通过检索Medline和Embase数据库、人工文献回顾以及个人藏书,对报告无症状先天性巨细胞病毒感染儿童听力和神经发育结局的原始数据的文章进行系统文献综述。国际前瞻性系统评价注册编号为CRD42015025407。
在1969年至2016年间识别出的480篇文章中,有37篇符合纳入标准。其中29篇提供了听力结局的原始数据,20篇提供了神经发育结局的原始数据(37项研究中的12项提供了两方面的数据)。随访至少5年的感音神经性听力损失累积发生率为7%至11%,高于健康对照儿童,但低于有症状先天性巨细胞病毒感染的儿童(34%-41%)。听力损失的发病、病程和严重程度各不相同,没有可靠的病毒学预后标志物。与对照组相比,无症状先天性巨细胞病毒感染儿童在神经发育评估中的表现并不比对照组差,且优于有症状先天性巨细胞病毒感染的儿童。
研究表明,无症状先天性巨细胞病毒感染儿童发生听力损失的风险增加,但与健康对照儿童相比,在神经发育评估中的表现相当。没有可靠的病毒学标志物来确定哪些婴儿会出现后遗症。文献支持对患儿进行定期随访直至入学。